NuVasive, Inc. (NUVA) Shares Sold by Disciplined Growth Investors Inc. MN

Disciplined Growth Investors Inc. MN decreased its position in NuVasive, Inc. (NASDAQ:NUVA) by 6.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,007 shares of the medical device company’s stock after selling 4,650 shares during the quarter. Disciplined Growth Investors Inc. MN owned 0.13% of NuVasive worth $3,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in NuVasive by 9.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock worth $146,000 after buying an additional 158 shares during the last quarter. Howard Hughes Medical Institute lifted its position in NuVasive by 82.8% in the 2nd quarter. Howard Hughes Medical Institute now owns 2,066 shares of the medical device company’s stock worth $159,000 after buying an additional 936 shares during the last quarter. Zions Bancorporation bought a new stake in NuVasive in the 3rd quarter worth approximately $160,000. Shelton Capital Management bought a new stake in NuVasive in the 2nd quarter worth approximately $221,000. Finally, Verition Fund Management LLC bought a new stake in NuVasive in the 2nd quarter worth approximately $233,000.

NuVasive, Inc. (NASDAQ NUVA) opened at $57.96 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.51 and a current ratio of 2.85. NuVasive, Inc. has a 12 month low of $49.25 and a 12 month high of $81.68. The stock has a market capitalization of $2,964.81, a P/E ratio of 30.78, a PEG ratio of 2.07 and a beta of 0.77.

NuVasive (NASDAQ:NUVA) last posted its earnings results on Tuesday, October 24th. The medical device company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.04. NuVasive had a return on equity of 13.65% and a net margin of 6.36%. The firm had revenue of $247.40 million for the quarter, compared to analysts’ expectations of $255.70 million. During the same period in the previous year, the firm earned $0.40 earnings per share. The business’s revenue was up 3.3% compared to the same quarter last year. sell-side analysts anticipate that NuVasive, Inc. will post 1.91 EPS for the current fiscal year.

NuVasive declared that its board has initiated a stock buyback plan on Tuesday, October 24th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the medical device company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

A number of research firms recently weighed in on NUVA. Royal Bank of Canada restated a “buy” rating and issued a $85.00 target price on shares of NuVasive in a research report on Monday, August 21st. Gabelli restated a “buy” rating on shares of NuVasive in a research report on Thursday, September 21st. Cowen reiterated an “outperform” rating and issued a $83.00 price objective on shares of NuVasive in a research report on Monday, September 18th. BTIG Research started coverage on NuVasive in a research report on Thursday, September 7th. They issued a “buy” rating and a $82.00 price objective for the company. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price objective (down previously from $75.00) on shares of NuVasive in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company’s stock. NuVasive presently has an average rating of “Buy” and an average target price of $72.36.

COPYRIGHT VIOLATION NOTICE: “NuVasive, Inc. (NUVA) Shares Sold by Disciplined Growth Investors Inc. MN” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/12/12/nuvasive-inc-nuva-shares-sold-by-disciplined-growth-investors-inc-mn.html.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply